Clinical trials
Mumps trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 4 |
| 2014 | 2 |
| 2022 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Recruiting | 2 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 10 |
| Sanofi Pasteur, a Sanofi Company | 3 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Children's Mercy Hospital Kansas City | 1 |
| CyanVac LLC | 1 |
| Novartis Vaccines | 1 |
| Sri Edupuganti, MD MPH | 1 |
| The Plasma Source | 1 |
| University of Michigan | 1 |
| University of Rochester | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mumps | 22 |
| Measles | 21 |
| Rubella | 20 |
| Chickenpox | 11 |
| Haemophilus Infections | 3 |
| Meningitis, Meningococcal | 3 |
| Giardiasis | 1 |
| Herpes Simplex | 1 |
| Hyper-IgM Immunodeficiency Syndrome, Type 1 | 1 |
| Meningitis | 1 |
Trials
Showing 51 to 22 of 22. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.